# Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Source: https://onco.cc/trials/nct05922930/  
OnCo record `nct05922930` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT05922930 as active not recruiting, last updated 2026-09-25. Enrolment is 51 planned participants, an estimate. Interventions: TROP2-CAR-NK, Cyclophosphamide, Fludarabine. Primary measures include Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Registry id: NCT05922930
- Phase: 1/2
- Setting: Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT05922930: https://clinicaltrials.gov/study/NCT05922930

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct05922930.json